08:00 , Jan 19, 2015 |  BC Week In Review  |  Clinical News

99mTc-rhAnnexin V-128: Phase I/IIa started

Advanced Accelerator Applications began an open-label Phase I/IIa trial to evaluate 0.4 mg IV 99mTc-rhAnnexin V-128 given at day 1 and following treatment with biological DMARD therapies in about 20 patients. The company has exclusive...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Company News

Atreus Pharmaceuticals, Advanced Accelerator Applications deal

Advanced Accelerator Applications (AAA) acquired the remaining 49.9% of Atreus that it did not already own and renamed the fully owned subsidiary to AAA Canada. Through the acquisition, AAA gains 99mTc-rhAnnexin V-128 , which is...